A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

NCT03713242 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Impairment

Interventions

DRUG: ACT-541468 25 mg
DRUG: ACT-541468 25 mg (or 10 mg depending on interim results)

Sponsor

Idorsia Pharmaceuticals Ltd.